Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbutin, Tretinoin, and Triamcinolone vs Triluma for Facial Melasma
NCT00717652Phase 3Suspended
- Sponsor
- Azidus Laboratories Limited
- Start
- Jul 2008
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of arbutin, tretinoin and triamcinolone in melasma (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Melasma Area and Severity Index at 12 weeks. Started Jul 2008; status: suspended.
02
Drugs
arbutintretinointriamcinolone
03
Conditions
melasma
Beyond the preview
Go deeper on NCT00717652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00717652.